Tradestie Institutional Equity Comparison Engine

ABCL vs MESO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ABCL Overall Edge

ABCL Captures Institutional Edge (3โ€“1 Pillars ยท 5โ€“5 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to AbCellera Biologics Inc. Common Shares (ABCL) driven by superior Valuation, Momentum & Technical, Options & Structure while MESO counters with relative strength in Growth & Margin. Fundamentally, ABCL trades at 27.6x Forward P/E with -1550.0% operating margin (-76.3% YoY revenue) versus MESO at N/M Forward P/E and -42.6% operating margin (+390.7% YoY). In options structure, ABCL sits in CONSOLIDATION (25th %ile IV; Dealer Gamma Walls on Pro) against MESO sits in UNCLASSIFIED (37th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ABCL
ABCL 27.6x vs MESO N/M Fwd P/E
Growth & Margin Winner MESO
Op Margin -1550.0% vs -42.6% ยท YoY -76.3% vs +390.7%
Momentum & Technical Winner ABCL
1Y +209.0% vs -16.4% ยท 52W Pos 69% vs 6%
Options & Structure Winner ABCL
CONSOLIDATION (25th %ile IV) vs UNCLASSIFIED (37th %ile IV)
ABCL NASDAQ
AbCellera Biologics Inc. Common Shares
Pharmaceutical Preparations
$11.19
-2.65% 1D
Market Cap $3.8B
1M Return -5.21%
1Y Return +208.98%
Forward P/E 27.6x
Unified AI Score
63.3 / 100 BUY
Tech 57.0 Fund 58.0 Flow 67.0 Mom 54.0
MESO NASDAQ
Mesoblast Limited American Depositary Shares
Biological Products, (No Diagnostic Substances)
$12.47
-6.03% 1D
Market Cap $1.7B
1M Return -6.1%
1Y Return -16.42%
Forward P/E N/M
Unified AI Score
35.5 / 100 SELL
Tech 25.0 Fund 40.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ABCL +208.98% MESO -16.42% Spread: +225.4 pp (ABCL Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ABCL TTM Op. Margin: -1550.0% MESO TTM Op. Margin: -42.6%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABCL vs MESO. Trailing 12-month operating profitability (ABCL -1550.0% vs MESO -42.6%) and valuation multiples (ABCL 27.6x vs MESO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ABCL (5) vs MESO (5)
Institutional Metric ABCL MESO Criterion Row Winner
Market Capitalization Scale $3.8B $1.7B Larger Scale ABCL
Trailing P/E Ratio Valuation 27.6x N/M Lower Multiple ABCL
Forward P/E Ratio Valuation 27.6x N/M Lower Multiple ABCL
Revenue Growth (YoY) Growth -76.3% +390.7% Higher Growth MESO
Operating Margin (TTM) Profitability -1550.0% -42.6% Higher Margin MESO
Net Profit Margin Profitability -248.8% -47.8% Higher Margin MESO
Return on Equity (ROE) Capital Efficiency -17.3% -9.9% Higher ROE MESO
52-Week Range Position Momentum 69% ($3โ€“$15) 6% ($12โ€“$22) Stronger Trend ABCL
Beta / 30D Volatility Risk Regime 2.31ฮฒ ยท 87% Vol 1.18ฮฒ ยท 78% Vol Lower Realized Risk MESO
Unified Institutional Score Composite Signal 63.3 / 100 (BUY) 35.5 / 100 (SELL) Higher Composite ABCL

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ABCL vs MESO Buy Guide
ABCL CONSOLIDATION
34d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 25th %ile
IV Regime Compressed (<25th %ile)
Live ABCL Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MESO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 37th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MESO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ABCL nor MESO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.